10-Q quarterly report · filed Nov 4, 2026

Relay Therapeutics, Inc. (RLAY) Q3 2026 10-Q Quarterly Report

Short answer

Relay Therapeutics, Inc. (RLAY) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$82M.

Q3 2026 key financials · XBRL

Revenue
$0
−100.0% QoQ
Net income
−$82M
−10.2% YoY · +2.3% QoQ
EPS (diluted)
−$0.37
+14.0% YoY · +9.8% QoQ

Source: XBRL data from the Relay Therapeutics, Inc. (RLAY) Q3 2026 10-Q on SEC EDGAR. USD.

Relay Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0 vs $0 YoY, with no product sales
  • Net loss $81.7M vs $74.1M YoY, operating loss $90.2M vs $80.4M
  • R&D expense $77.1M vs $68.3M, clinical-trial costs $45.2M vs $34.0M
  • Cash, equivalents and investments $848.6M, operating cash outflow $169.2M through nine months
  • May offering generated $296.8M net; cash expected to fund operations into 2029, with continued financing needs ahead

Risk Factors

  • New regulatory risk: BIOSECURE Act enacted December 18, 2025, potentially restricting WuXi AppTec arrangements from 2027 or later
  • Most material operational update: WuXi AppTec’s 1260H designation litigation, preliminary injunction granted August 7, 2026
  • Clinical risk: FDA may require a companion diagnostic for zovegalisib in biomarker-defined populations
  • Financial risk: $238.7 million net loss and $2.3 billion accumulated deficit as of September 30, 2026
  • Funding risk: $463.0 million remaining at-the-market common-stock capacity, subject to dilution risk

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Relay Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.